Canopy Growth Corp (CGC) fair value: what the stock is really worth
As of Oct 12, 2026: fair value of Canopy Growth Corp $0.15, price $0.76, upside -79.8%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 12, 2026.
How to read this chart
60‑month range $0.7575 – $222.30 · fair‑value band $0.1020 – $0.1870 · the $0.7575 price screens above the $0.1530 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 12, 2026.
Follow Canopy Growth in your weekly email
Every Wednesday you see whether Canopy Growth is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works.
Show more
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, and Claybourne brands, as well as DOJA, LivRelief, Ace Valley, and Vert brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Stock analysis
Canopy Growth Corp (CGC) currently trades at $0.7575, while our model-based Fair Value estimate is $0.1530, 79.8% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $0.1020 (bear) to $0.1870 (bull), the price of $0.7575 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Canopy Growth Corp reported revenue of C$285M in FY2026 versus C$476M in FY2022, a compound −12.1%/yr. Reported net income was −C$263M in FY2026.
Key figures
Market cap $393M · P/S ratio 1.34 · EPS (TTM) $−0.4700 · Net margin −92.4% · Return on equity −39.5% · Return on assets (EBIT) −32.6% · Operating margin −21.7% · Revenue (TTM) C$294M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (medium confidence).
What moves the price
The share trades about 61% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at −80%, CGC screens richer than that median.
Fair Value models
Bear $0.1020Fair Value $0.1530Bull $0.1870
Price $0.7575 · Upside -79.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+5.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.2%
Start year 2021 (pandemic). Over 10 years: +36.5% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+127.6%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−227.5% (2021) → −25.7% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 588 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside−79.8% · Bottom 25%
Profitability
Return on assets−3.9% · Bottom 25%
Net margin (TTM)−79.2% · Bottom 25%
Operating margin (TTM)−21.7% · Bottom 25%
Growth and dividend
Revenue growth12.5% · Above median
Balance sheet
Debt / equity0.31× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.56× · Cheapest 25%
P/S (TTM)1.34× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 16
FUTURE (revenue growth)63· sector 25
PAST (return on equity)0· sector 27
HEALTH (low debt)84· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Canopy Growth Corp (CGC) overvalued or undervalued?
As of Oct 12, 2026, our model estimates a fair value of $0.1530 versus a price of $0.7575, about −80% upside (overvalued).
What is the fair value of CGC?
Our model-based fair value for Canopy Growth Corp is $0.1530 (as of Oct 12, 2026), built from audited fundamentals. The current price: $0.7575.
What is the quality score of CGC?
Canopy Growth Corp has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Canopy Growth Corp (CGC)?
Our model-based price target is the fair value of $0.1530 (as of Oct 12, 2026) from 1 valuation models. Cautious scenario $0.1020, optimistic scenario $0.1870. It is a calculation from audited fundamentals, not an analyst target.
What is the Canopy Growth Corp stock forecast for 2026?
Our models put fair value at $0.1530, about −80% upside versus a price of $0.7575 (overvalued). Cautious scenario $0.1020, optimistic scenario $0.1870. The calculation is refreshed regularly with new filings.
What is the revenue of Canopy Growth Corp (CGC)?
Canopy Growth Corp reported trailing-twelve-month revenue of about C$294M (latest available figure, as of Oct 12, 2026).
What is the intrinsic value of Canopy Growth Corp (CGC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Canopy Growth Corp it is $0.1530 per share (as of Oct 12, 2026), against a price of $0.7575. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Canopy Growth Corp stock overvalued or undervalued in 2026?
As of Oct 12, 2026, CGC trades above its calculated fair value: price $0.7575, fair value $0.1530, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CGC?
No. The price is what the market pays today ($0.7575); the fair value is what the company's own numbers justify ($0.1530). For Canopy Growth Corp the two are $0.6045 per share apart. That gap is exactly why we show both numbers side by side.
How much is Canopy Growth Corp worth?
The market values Canopy Growth Corp at about $393M (market capitalisation, as of Oct 12, 2026). Per share that is $0.7575; our models calculate a fair value of $0.1530 per share.
What do the bullish and bearish scenarios say about CGC?
Our models span a range for Canopy Growth Corp: cautious scenario $0.1020, base $0.1530, optimistic $0.1870 per share (as of Oct 12, 2026, price $0.7575). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Canopy Growth Corp (CGC)?
Balance-sheet figures for Canopy Growth Corp (as of Oct 12, 2026): return on equity −39.5%, debt of 0.31 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is CGC from its 52-week high?
Canopy Growth Corp trades at $0.7575, about 61% below its 52-week high of $1.92 and at the low of $0.7575 (as of Oct 12, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1530 is for.
Which stocks are comparable to Canopy Growth Corp?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Canopy Growth Corp stock attractive at the current price?
The data as of Oct 12, 2026: price $0.7575, calculated fair value $0.1530 (−80%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CGC calculated?
We run Canopy Growth Corp through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1530, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.8 % above its aggregate fair value. Canopy Growth Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Canopy Growth Corp (CGC)?
The closing price on Oct 12, 2026 was $0.7575. Our model-based fair value is $0.1530, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Canopy Growth Corp right now?
The price sits above even our optimistic bull case ($0.1870). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1020 to $0.1870) leaves room in how you read the outcome.
Key figures of Canopy Growth Corp
How large is the market capitalisation of Canopy Growth Corp (CGC)?
The market capitalisation of Canopy Growth Corp is $393M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Canopy Growth Corp (CGC)?
The price-to-sales ratio of Canopy Growth Corp is 1.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Canopy Growth Corp (CGC)?
Earnings per share at Canopy Growth Corp are $−0.4700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Canopy Growth Corp (CGC)?
The net margin of Canopy Growth Corp is −92.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Canopy Growth Corp (CGC)?
The return on equity (ROE) of Canopy Growth Corp is −39.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Canopy Growth Corp (CGC)?
On an EBIT basis the return on assets of Canopy Growth Corp is −32.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Canopy Growth Corp (CGC)?
The operating margin of Canopy Growth Corp is −21.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Canopy Growth Corp (CGC)?
Revenue at Canopy Growth Corp is growing +12.5% versus a year earlier (3y avg −5.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Canopy Growth Corp (CGC) generate?
The free cash flow of Canopy Growth Corp is −C$69.8M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Canopy Growth Corp (CGC) hold?
Canopy Growth Corp holds more cash than debt, C$86.0M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Canopy Growth Corp in the live analysis
One click puts Canopy Growth Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 12, 2026